We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Scientists Validate Method to Measure Protein Interactions

By Biotechdaily staff writers
Posted on 04 May 2004
Researchers working with the p73 homologue of the tumor-suppressor gene p73 have described the mechanism by which the Wwox tumor suppressor protein interacts with p73, an interaction that increases apoptosis and decreases the likelihood of tumor development.

The p73 gene shares many structural and functional features of p53, including a 63% homology with a remarkable conservation of critical residues that are known to be important for the binding of p53 to target genes or proper folding of p53. More...
The C-terminal domain of p53 and p73 are quite distinct, however. The p73 gene has been mapped to human chromosome 1p36, a region that is frequently deleted in a variety of human cancers including neuroblastoma, colon cancer, and breast cancer.

Scientists at Thomas Jefferson University (Philadelphia, PA, USA) and researchers at Cytogen Corp. (Princeton, NJ, USA) reported in the March 30, 2004, issue of the Proceedings of the [U.S.] National Academy of Sciences that Wwox physically interacted via its first WW domain with the p53 homologue, p73. The tyrosine kinase, Src, phosphorylated Wwox at tyrosine 33 in the first WW domain and enhanced its binding to p73. Wwox expression triggered redistribution of nuclear p73 to the cytoplasm and, hence, suppressed its transcriptional activity. In addition, cytoplasmic p73 contributed to the activity of Wwox leading to apoptosis. These findings were obtained using Cytogen's in vitro signal transduction pathway discovery platform.

"In the present study, we have demonstrated the physical interaction between the recently discovered Wwox and the p53 homologue, p73,” explained senior author Dr.Carlo Croce, professor of microbiology and immunology at Thomas Jefferson University. "Since the Wwox protein contains two WW domains that are generally known to mediate protein-protein interaction, Cytogen's robust WW domain interaction data allowed us to efficiently reveal a functional cross-talk between p73 and the Wwox tumor suppressor protein. The study results help establish that the company's high-throughput method to measure protein interactions compares favorably with other more complex techniques and further validates this method of elucidating and identifying protein interactions.”





Related Links:
Thomas Jefferson University
Cytogen Corp.

New
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Gold Member
Quality Control Material
iPLEX Pro Exome QC Panel
New
All-in-One Molecular System
AIO M160
New
Benchtop Thermomixer
Biometra TS1 ThermoShaker
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.